What is the appropriate hydroxyzine dose for treating sleep‑related bruxism in children?

Hydroxyzine Dose for Sleep-Related Bruxism in Children

Based on limited evidence, hydroxyzine 10-25 mg at bedtime can be considered for sleep-related bruxism in children, though this remains an off-label use with very limited supporting data.

Evidence Base and Dosing

The only direct evidence for hydroxyzine in pediatric sleep bruxism comes from a small case series 1 reporting three children treated with 10-25 mg per night with significant reduction in bruxism severity over 1-2 months, without adverse effects. However, this represents very low-quality evidence (case reports only).

A 2024 meta-analysis 2 found hydroxyzine had modest efficacy (OR 0.19; 95% CI 0.03-1.04) for pediatric bruxism, though photobiomodulation showed superior results. A 2026 systematic review 3 in adults found no medication can be recommended for routine SB management, emphasizing that pharmacotherapy should not replace first-line behavioral approaches.

FDA-Approved Dosing Context

According to the FDA label 4, hydroxyzine dosing for approved indications in children is:

• Children under 6 years: 50 mg daily in divided doses
• Children over 6 years: 50-100 mg daily in divided doses
• As sedative: 0.6 mg/kg body weight

For bruxism specifically, the reported effective range of 10-25 mg at bedtime 1 is substantially lower than FDA-approved dosing for other indications, likely targeting mild sedation rather than anxiolysis.

Critical Safety Considerations

Before prescribing hydroxyzine, you must understand these risks 5, 4:

• Performance impairment: First-generation antihistamines like hydroxyzine cause daytime drowsiness, decreased alertness, and impaired learning/school performance in children, even when dosed only at bedtime due to prolonged half-lives
• Paradoxical CNS stimulation: Can occur particularly in children
• QT prolongation/Torsade de Pointes: Use with extreme caution if any cardiac risk factors present 4
• Anticholinergic effects: Dry mouth, constipation, urinary retention
• AGEP risk: Rare but serious skin reaction 4

Recommended Clinical Approach

First-line management should always be non-pharmacologic 3, 6:

1. Behavioral interventions: Habit reversal training, biofeedback, counseling with self-management
2. Sleep hygiene optimization: Regular sleep schedule, stress reduction
3. Dental appliances: Occlusal guards to prevent tooth damage
4. Address underlying factors: Anxiety, sleep disorders, medications that may worsen bruxism (SSRIs, stimulants) 7

If pharmacotherapy is considered after behavioral approaches fail:

• Start with 10 mg at bedtime (lower end of reported range)
• Titrate to maximum 25 mg based on response
• Assess efficacy after 1 month 1
• Monitor for daytime sedation, school performance, and behavioral changes
• Ensure parents understand this is off-label use with limited evidence
• Consider trial discontinuation after 2-3 months to assess ongoing need

Key Pitfalls to Avoid

• Do not use hydroxyzine as first-line therapy - behavioral approaches should be attempted first
• Do not assume bedtime dosing avoids daytime effects - hydroxyzine has prolonged effects that persist into the next day 5
• Do not prescribe without cardiac screening if any history of syncope, palpitations, or family history of sudden cardiac death 4
• Do not combine with other CNS depressants without dose reduction 4
• Do not use in elderly patients (though not applicable here) due to increased fall risk and cognitive impairment

The evidence for hydroxyzine in pediatric sleep bruxism is extremely limited, and this should be clearly communicated to families as an off-label trial when conservative measures have been exhausted.